Latigo Biotherapeutics (LTGO) SEC Filings, Aug 6, 2026

Latigo Biotherapeutics, Inc. (LTGO) received an initial ownership report from Beth C. Seidenberg, who is a director and more than 10% owner. The filing lists only indirect holdings in preferred stock series and a convertible note, held through Westlake BioPartners funds and an opportunity fund, each convertible into shares of common stock, generally upon the closing of Latigo’s initial public offering. Seidenberg, as sole managing director of the relevant general partners, has voting and dispositive power over these fund-held securities but disclaims Section 16 beneficial ownership except to the extent of her pecuniary interest.